 CD-47 is overexpressed in many different types of cancer, making it an attractive target for therapeutic intervention. Researchers have developed two novel radio-labeled nanobody C2 and ABDC2 that bind to CD-47 and can be used as imaging probes or as part of a theranostic approach. The nanobodies were tested in preclinical models and found to be highly specific for CD-47, with high affinity and long half-lives. They also demonstrated excellent tumor uptake and retention, suggesting their potential use in clinical applications. This article was authored by Yu Zhang, Di Zhang, Xu Xianen, and others.